IndieBio

Ten63 Therapeutics, Inc. is a biotechnology company based in Chapel Hill, North Carolina, focused on developing potent therapeutics for medically validated yet undruggable targets. Founded in 2017, the company utilizes its innovative platform, COPPER, which combines machine learning-based computational chemistry with advanced physical modeling to explore an extensive chemical space. This approach allows Ten63 Therapeutics to discover novel drug candidates for some of the most lethal diseases by employing proprietary algorithms for scaffold redesign and optimizing chemical design. By integrating these technologies, the company aims to produce durable therapies and improve drug resistance prediction, ultimately addressing challenges in drug development for previously intractable targets.

BioLattice is a biotechnology company focused on developing tissue-engineered cornea technology. Their primary goal is to provide a viable alternative to donor tissue for full-thickness corneal transplants. The company's innovative technology offers a corneal prototype with vision-correcting capabilities, aiming to restore sight for patients requiring corneal transplants.

ViAn Therapeutics is an early-stage biotechnology company dedicated to innovating treatments for retinal diseases. The company is developing a first-in-class, non-invasive eyedrop treatment aimed at replacing traditional invasive injections for conditions such as age-related macular degeneration and diabetic macular edema. With robust preclinical data and ongoing clinical testing, ViAn is poised to address significant unmet medical needs within the retinal disease sector, which represents a substantial market opportunity. In addition to its focus on ophthalmology, ViAn is also engaged in creating peptide drugs designed to inhibit angiogenesis, potentially benefiting patients suffering from cancer and other angiogenesis-dependent diseases. Through its innovative approaches, ViAn Therapeutics seeks to enhance patient outcomes and improve the overall quality of life for individuals affected by these conditions.

Laguna Bio is a biotechnology company focused on cancer treatment through its innovative drug discovery platform. Founded in 2022 and headquartered in Berkeley, California, the company specializes in selectively activating and expanding the innate immune system to combat solid tumors. By enhancing the response rate of bispecific antibody drugs, Laguna Bio aims to provide specific T cells that strengthen the immune system's ability to fight cancer, ultimately improving survival rates for patients facing this deadly disease.

FREZENT is a biotechnology company focused on developing innovative therapeutics for advanced-stage cancer patients. It specializes in creating biological inhibitors that target cancer-specific lipid metabolism, aiming to prevent the reactivation of dormant cancer cells.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

HelEx is a biotechnology company founded in 2021 and based in New York, specializing in genomic medicines tailored for renal indications. The company utilizes its proprietary genomics data and bioinformatics to develop, validate, and distribute therapy-specific guide RNAs (gRNAs). HelEx's innovative platform leverages data-driven deep-learning modeling, utilizing high-throughput next-generation sequencing data derived from CRISPR edits on human cell lines. This approach provides reliable predictions and allows for in-house validation, thereby facilitating the acceleration of drug discovery and the development of cell and gene therapies in the CRISPR-based market.

Calder Biosciences is a biotechnology company focused on developing advanced vaccines to combat life-threatening viruses. Recognizing that traditional vaccines often fail to provide adequate protection against evolving viral threats, Calder employs its proprietary 3D-Vaxlock technology, which utilizes structure-based design to enhance the stability and efficacy of vaccine candidates. This innovative platform creates molecular staples that maintain vaccines in their most effective configurations, addressing the common shortcomings of subunit vaccines, such as limited potency and shelf-life. Calder's current projects include a universal flu vaccine aimed at covering all seasonal strains and a respiratory syncytial virus (RSV) vaccine tailored for the elderly. By prioritizing the development of vaccines with exceptional safety, efficacy, and durability, Calder aims to reduce severe disease and mortality rates while alleviating the burden on healthcare systems, ultimately contributing to healthier lives for vulnerable populations.

Cayuga Biotech is a startup focused on the development of innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a major cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting process at the injury site, thereby minimizing the risk of side effects associated with bleeding. Cayuga's pipeline includes a clinic-ready drug designed for life-threatening hemorrhage and additional therapeutics in the discovery stage targeting rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. Through its biomimetic therapeutics technology, Cayuga Biotech seeks to harness the body's innate ability to promote healing and improve survival rates, while also reducing disability resulting from trauma.

RyboDyn is a biotechnology research company focused on developing innovative therapeutics aimed at training the immune system to identify and eliminate cancer from within the body. By leveraging cutting-edge scientific breakthroughs, RyboDyn creates advanced treatments that promise significant improvements in the management of terminal diseases and various ailments. The company's commitment to enhancing medicine through its research positions it at the forefront of the fight against cancer, with the potential to transform patient care and outcomes.

RizLab Health is a medical device startup founded in 2018 and based in East Princeton. The company specializes in providing rapid blood count analysis through its innovative electronic cytometer and analyzer. This device utilizes a cartridge system to quantify key cellular components of white blood cells, facilitating quick and accurate assessments of patients' health. RizLab Health's technology is designed to be portable and cost-effective, enabling healthcare practitioners to monitor white blood counts, neutrophils, and lymphocytes efficiently. This capability is particularly valuable in clinical scenarios such as diagnosing sepsis or determining the presence of bacterial or viral infections, enhancing decision-making in patient care.

FREZENT is a biotechnology company focused on developing innovative therapeutics for advanced-stage cancer patients. It specializes in creating biological inhibitors that target cancer-specific lipid metabolism, aiming to prevent the reactivation of dormant cancer cells.

BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is dedicated to improving reconstruction options for breast cancer patients post-mastectomy. The company specializes in developing tissue-engineered nipple-areolar complex (NAC) grafts, which are designed to be used during the breast reconstruction phase. These off-the-shelf, acellular NAC grafts serve as a framework for the patient's own cells to regenerate their nipple and areola, providing a more natural outcome. The company is based in New Orleans, Louisiana.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Calder Biosciences is a biotechnology company focused on developing advanced vaccines to combat life-threatening viruses. Recognizing that traditional vaccines often fail to provide adequate protection against evolving viral threats, Calder employs its proprietary 3D-Vaxlock technology, which utilizes structure-based design to enhance the stability and efficacy of vaccine candidates. This innovative platform creates molecular staples that maintain vaccines in their most effective configurations, addressing the common shortcomings of subunit vaccines, such as limited potency and shelf-life. Calder's current projects include a universal flu vaccine aimed at covering all seasonal strains and a respiratory syncytial virus (RSV) vaccine tailored for the elderly. By prioritizing the development of vaccines with exceptional safety, efficacy, and durability, Calder aims to reduce severe disease and mortality rates while alleviating the burden on healthcare systems, ultimately contributing to healthier lives for vulnerable populations.

Cell BioEngines, Inc. is a clinical-stage biotechnology company dedicated to the development of allogeneic "off-the-shelf" stem cell therapies aimed at treating various human diseases. The company employs a unique blood stem cell-derived epigenetic platform designed to enhance donor source availability, improve cellular potency, and simplify the manufacturing processes of clinical-grade cell products. In addition, Cell BioEngines is advancing a pre-clinical stage immunotherapy platform focused on making all cancers treatable, thereby offering the potential for long-lasting benefits in oncology. Through its innovative approach, Cell BioEngines seeks to address significant challenges in the field of cell-based therapies and improve patient outcomes.

Cayuga Biotech is a startup focused on the development of innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a major cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting process at the injury site, thereby minimizing the risk of side effects associated with bleeding. Cayuga's pipeline includes a clinic-ready drug designed for life-threatening hemorrhage and additional therapeutics in the discovery stage targeting rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. Through its biomimetic therapeutics technology, Cayuga Biotech seeks to harness the body's innate ability to promote healing and improve survival rates, while also reducing disability resulting from trauma.

FluoSphera is a biotechnology company focused on developing safer and more effective drugs. It aims to minimize adverse side effects and reduce reliance on animal testing by leveraging innovative drug discovery technologies. This enables FluoSphera's partners to better understand human physiological responses and safeguard populations from harmful chemicals more efficiently.

BiomeSense, Inc. is a Chicago-based company founded in 2018 that focuses on developing a comprehensive platform for microbiome data collection and analysis. Its primary innovation is the GutLab, a "smart bathroom" system designed for continuous, at-home monitoring of the human gut microbiome. This technology is integrated with the MetaBiome time-series analytics platform, offering a seamless end-to-end solution that enables real-time tracking of microbiome changes and their correlation with clinical outcomes. By generating and analyzing extensive longitudinal microbiome datasets, BiomeSense aims to discover and commercialize novel microbiome biomarkers, providing healthcare professionals with a high-resolution microbiome database. This resource supports the development of advanced microbiome-based therapeutics and consumer products, ultimately enhancing precision medicine and improving health outcomes.

BioROSA Technologies Inc. is a biotechnology company focused on developing diagnostic tools for Autism Spectrum Disorders (ASD). Founded in 2018 and headquartered in Belmont, Massachusetts, the company specializes in creating biologically-based blood tests that assist clinicians in identifying individuals at risk for ASD. By utilizing machine learning to analyze biological data, BioROSA Technologies aims to provide reliable and accurate diagnoses, facilitating early detection and timely treatment. Additionally, the company's technology supports therapeutic trials by evaluating pharmacodynamics and patient stratification, thereby enhancing the overall standard of care for ASD.

FluoSphera is a biotechnology company focused on developing safer and more effective drugs. It aims to minimize adverse side effects and reduce reliance on animal testing by leveraging innovative drug discovery technologies. This enables FluoSphera's partners to better understand human physiological responses and safeguard populations from harmful chemicals more efficiently.

BioSapien is a pre-clinical biotechnology company focused on developing innovative biodegradable implantable products for targeted drug delivery in oncology. The company is creating a 3D-printed drug delivery platform known as MediChip, which is designed to administer active pharmaceutical ingredients in a localized and sustained manner. This technology aims to reduce systemic side effects associated with high-dose systemic therapies by delivering drugs directly to cancerous tumor sites. Currently, BioSapien's applications are being explored for pancreatic and lung cancers, with plans to expand its pipeline to include other cancer types such as colorectal, breast, and stomach cancers. The biodegradable mesh used in their products allows for effective treatment while improving patients' quality of care and life.

HelEx is a biotechnology company founded in 2021 and based in New York, specializing in genomic medicines tailored for renal indications. The company utilizes its proprietary genomics data and bioinformatics to develop, validate, and distribute therapy-specific guide RNAs (gRNAs). HelEx's innovative platform leverages data-driven deep-learning modeling, utilizing high-throughput next-generation sequencing data derived from CRISPR edits on human cell lines. This approach provides reliable predictions and allows for in-house validation, thereby facilitating the acceleration of drug discovery and the development of cell and gene therapies in the CRISPR-based market.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Intrinsic Medicine, Inc. is a clinical-stage company based in Des Moines, Washington, focused on researching and developing innovative medicines for patients. Formerly known as Lupa Bio, the company specializes in the development of prebiotic drugs aimed at treating various human diseases. Its flagship products, Human Identical Milk Oligosaccharides (HiMOs), are engineered to remain stable in stomach acid and resist degradation in the upper gastrointestinal tract. This unique formulation allows patients to enhance gut health and modulate immune responses effectively. As a venture-backed entity, Intrinsic Medicine operates with a technical and operational platform designed to bring significant medical advancements to patients in an efficient and ethical manner.

Laguna Bio is a biotechnology company focused on cancer treatment through its innovative drug discovery platform. Founded in 2022 and headquartered in Berkeley, California, the company specializes in selectively activating and expanding the innate immune system to combat solid tumors. By enhancing the response rate of bispecific antibody drugs, Laguna Bio aims to provide specific T cells that strengthen the immune system's ability to fight cancer, ultimately improving survival rates for patients facing this deadly disease.

Melio is a healthcare company based in Santa Clara, California, specializing in blood testing technology aimed at detecting prevalent infections. The company has developed a comprehensive blood test platform that identifies common pathogens responsible for bloodstream infections. Utilizing a patented melting technique followed by detailed analysis, Melio's technology enables quick and accurate identification of blood-based pathogens. This innovation allows healthcare providers to deliver timely and targeted treatment, addressing the urgent need for effective therapies while also contributing to the fight against antibiotic resistance.

SyntheX, Inc. is a biotechnology company based in San Francisco, California, founded in 2016. It operates a proprietary drug discovery platform that utilizes synthetic biology to expand the druggable proteome, focusing on therapeutic applications in oncology and rare diseases. The platform employs empirical intracellular selection to identify and design compounds that can modulate protein interactions, either disrupting specific protein-protein interactions or facilitating the targeted degradation of proteins through the recruitment of E3 ubiquitin ligases. SyntheX's development portfolio includes stabilized peptide therapeutics, such as STX101 and STX105, aimed at treating cancers that evade chemotherapy through homologous recombination. The company identifies drug targets by analyzing clinical, evolutionary, phenotypic, and structural data, and it maintains both internal oncology projects and collaborative discovery initiatives.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Conan MedTech, founded in 2020 and based in Ithaca, New York, is focused on developing rapid point-of-care diagnostic tests for concussions. The company's innovative healthcare system aims to transform the diagnosis of mild traumatic brain injuries, enabling sports medicine doctors, athletic coaches, and trainers to make informed decisions on the sidelines during games. By providing real-time concussion detection and efficient medical assistance, Conan MedTech enhances the ability of medical professionals to assess athletes swiftly and improve their quality of life through timely interventions.

Conan MedTech, founded in 2020 and based in Ithaca, New York, is focused on developing rapid point-of-care diagnostic tests for concussions. The company's innovative healthcare system aims to transform the diagnosis of mild traumatic brain injuries, enabling sports medicine doctors, athletic coaches, and trainers to make informed decisions on the sidelines during games. By providing real-time concussion detection and efficient medical assistance, Conan MedTech enhances the ability of medical professionals to assess athletes swiftly and improve their quality of life through timely interventions.

Cayuga Biotech is a startup focused on the development of innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a major cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting process at the injury site, thereby minimizing the risk of side effects associated with bleeding. Cayuga's pipeline includes a clinic-ready drug designed for life-threatening hemorrhage and additional therapeutics in the discovery stage targeting rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. Through its biomimetic therapeutics technology, Cayuga Biotech seeks to harness the body's innate ability to promote healing and improve survival rates, while also reducing disability resulting from trauma.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Indee Labs is focused on developing innovative hardware for gene delivery, specifically designed to facilitate the efficient development and scalable manufacture of gene-modified cell therapies, such as chimeric antigen receptor T cells. The company has created a non-viral intracellular delivery system that integrates with standard reagents, optimizing the recovery of viable modified cells with minimal disruption. Utilizing microfluidic vortex shedding technology, Indee Labs' system enables the gentle delivery of macromolecules, nucleic acids, and gene-editing complexes to various cell types. The company collaborates with the Australian National Fabrication Facility for its technology development and has established lab space at Bonneville Labs in Berkeley while expanding its operations with a new office in Sydney. Indee Labs has been associated with various prestigious incubators and programs, including NSW Health, IndieBio, Y Combinator, and MBC Biolabs.

HelEx is a biotechnology company founded in 2021 and based in New York, specializing in genomic medicines tailored for renal indications. The company utilizes its proprietary genomics data and bioinformatics to develop, validate, and distribute therapy-specific guide RNAs (gRNAs). HelEx's innovative platform leverages data-driven deep-learning modeling, utilizing high-throughput next-generation sequencing data derived from CRISPR edits on human cell lines. This approach provides reliable predictions and allows for in-house validation, thereby facilitating the acceleration of drug discovery and the development of cell and gene therapies in the CRISPR-based market.

HelEx is a biotechnology company founded in 2021 and based in New York, specializing in genomic medicines tailored for renal indications. The company utilizes its proprietary genomics data and bioinformatics to develop, validate, and distribute therapy-specific guide RNAs (gRNAs). HelEx's innovative platform leverages data-driven deep-learning modeling, utilizing high-throughput next-generation sequencing data derived from CRISPR edits on human cell lines. This approach provides reliable predictions and allows for in-house validation, thereby facilitating the acceleration of drug discovery and the development of cell and gene therapies in the CRISPR-based market.

RizLab Health is a medical device startup founded in 2018 and based in East Princeton. The company specializes in providing rapid blood count analysis through its innovative electronic cytometer and analyzer. This device utilizes a cartridge system to quantify key cellular components of white blood cells, facilitating quick and accurate assessments of patients' health. RizLab Health's technology is designed to be portable and cost-effective, enabling healthcare practitioners to monitor white blood counts, neutrophils, and lymphocytes efficiently. This capability is particularly valuable in clinical scenarios such as diagnosing sepsis or determining the presence of bacterial or viral infections, enhancing decision-making in patient care.

RizLab Health is a medical device startup founded in 2018 and based in East Princeton. The company specializes in providing rapid blood count analysis through its innovative electronic cytometer and analyzer. This device utilizes a cartridge system to quantify key cellular components of white blood cells, facilitating quick and accurate assessments of patients' health. RizLab Health's technology is designed to be portable and cost-effective, enabling healthcare practitioners to monitor white blood counts, neutrophils, and lymphocytes efficiently. This capability is particularly valuable in clinical scenarios such as diagnosing sepsis or determining the presence of bacterial or viral infections, enhancing decision-making in patient care.

Filtricine, Inc., founded in 2017 and based in Santa Clara, California, is a clinical-stage biotechnology company focused on developing innovative therapies for cancer treatment. The company's approach involves targeted nutrient deprivation, which identifies and exploits metabolic vulnerabilities specific to cancer cells. By depleting nutrients critical to cancer growth without using traditional drugs, Filtricine aims to provide effective treatments that minimize harm to healthy cells.

Intrinsic Medicine, Inc. is a clinical-stage company based in Des Moines, Washington, focused on researching and developing innovative medicines for patients. Formerly known as Lupa Bio, the company specializes in the development of prebiotic drugs aimed at treating various human diseases. Its flagship products, Human Identical Milk Oligosaccharides (HiMOs), are engineered to remain stable in stomach acid and resist degradation in the upper gastrointestinal tract. This unique formulation allows patients to enhance gut health and modulate immune responses effectively. As a venture-backed entity, Intrinsic Medicine operates with a technical and operational platform designed to bring significant medical advancements to patients in an efficient and ethical manner.

Dalton Bioanalytics is a company that specializes in analytical technology aimed at transforming blood analysis and enhancing preventative healthcare. Founded in 2019 and based in Los Angeles, California, Dalton Bioanalytics addresses the inefficiencies and high costs associated with traditional laboratory testing. Its innovative technology digitizes the biochemical composition of blood, allowing for a comprehensive array of health insights derived from a single assay. This capability enables the monitoring of various plasma analytes, including proteins, lipids, electrolytes, and small molecules. By deciphering the biochemical signatures in blood, Dalton Bioanalytics supports the scientific research community in exploring multi-omic biology, thereby facilitating the discovery, development, and delivery of precision medicine.

Sequential Skin is a diagnostic platform focused on skin longevity and aging, leveraging expertise in genetics, epigenetics, and the skin microbiome. The company specializes in clinical microbiome testing for skin, scalp, and female health. Its primary offering is a skin health test that employs quantitative real-time PCR (qPCR) technology to analyze specific markers within the skin microbiome. This analysis provides individuals with a detailed understanding of their skin profile, helping them identify their unique skincare needs. By delivering personalized insights, Sequential Skin empowers individuals to make informed decisions about their skincare routines.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Ten63 Therapeutics, Inc. is a biotechnology company based in Chapel Hill, North Carolina, focused on developing potent therapeutics for medically validated yet undruggable targets. Founded in 2017, the company utilizes its innovative platform, COPPER, which combines machine learning-based computational chemistry with advanced physical modeling to explore an extensive chemical space. This approach allows Ten63 Therapeutics to discover novel drug candidates for some of the most lethal diseases by employing proprietary algorithms for scaffold redesign and optimizing chemical design. By integrating these technologies, the company aims to produce durable therapies and improve drug resistance prediction, ultimately addressing challenges in drug development for previously intractable targets.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Microbiome-focused therapeutics for diseases of the oral cavity and their systemic effects

BiomeSense, Inc. is a Chicago-based company founded in 2018 that focuses on developing a comprehensive platform for microbiome data collection and analysis. Its primary innovation is the GutLab, a "smart bathroom" system designed for continuous, at-home monitoring of the human gut microbiome. This technology is integrated with the MetaBiome time-series analytics platform, offering a seamless end-to-end solution that enables real-time tracking of microbiome changes and their correlation with clinical outcomes. By generating and analyzing extensive longitudinal microbiome datasets, BiomeSense aims to discover and commercialize novel microbiome biomarkers, providing healthcare professionals with a high-resolution microbiome database. This resource supports the development of advanced microbiome-based therapeutics and consumer products, ultimately enhancing precision medicine and improving health outcomes.

Mendel is a clinical AI platform for life sciences and healthcare organizations that deciphers health data with clinician-like logic. It indexes structured and unstructured data and replaces the complexity of querying with the simplicity of chatting.

BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is dedicated to improving reconstruction options for breast cancer patients post-mastectomy. The company specializes in developing tissue-engineered nipple-areolar complex (NAC) grafts, which are designed to be used during the breast reconstruction phase. These off-the-shelf, acellular NAC grafts serve as a framework for the patient's own cells to regenerate their nipple and areola, providing a more natural outcome. The company is based in New Orleans, Louisiana.

Intrinsic Medicine, Inc. is a clinical-stage company based in Des Moines, Washington, focused on researching and developing innovative medicines for patients. Formerly known as Lupa Bio, the company specializes in the development of prebiotic drugs aimed at treating various human diseases. Its flagship products, Human Identical Milk Oligosaccharides (HiMOs), are engineered to remain stable in stomach acid and resist degradation in the upper gastrointestinal tract. This unique formulation allows patients to enhance gut health and modulate immune responses effectively. As a venture-backed entity, Intrinsic Medicine operates with a technical and operational platform designed to bring significant medical advancements to patients in an efficient and ethical manner.

BrightCure Ltd., established in 2019 and based in London, United Kingdom, specializes in developing probiotic-based therapies aimed at treating urinary tract infections (UTIs). The company focuses on addressing recurrent and difficult-to-treat bacterial infections, a significant health issue affecting 50% of women and 12% of men globally. BrightCure's approach involves utilizing the natural microbiome to reduce harmful bacteria and replenish beneficial bacteria in the vaginal flora, thereby boosting the immune system to promote urinary tract health. The company has garnered recognition through various competitions and accelerators, including selection for Indiebio, the world's largest biotech accelerator.

BrightCure Ltd., established in 2019 and based in London, United Kingdom, specializes in developing probiotic-based therapies aimed at treating urinary tract infections (UTIs). The company focuses on addressing recurrent and difficult-to-treat bacterial infections, a significant health issue affecting 50% of women and 12% of men globally. BrightCure's approach involves utilizing the natural microbiome to reduce harmful bacteria and replenish beneficial bacteria in the vaginal flora, thereby boosting the immune system to promote urinary tract health. The company has garnered recognition through various competitions and accelerators, including selection for Indiebio, the world's largest biotech accelerator.

Cayuga Biotech is a startup focused on the development of innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a major cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting process at the injury site, thereby minimizing the risk of side effects associated with bleeding. Cayuga's pipeline includes a clinic-ready drug designed for life-threatening hemorrhage and additional therapeutics in the discovery stage targeting rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. Through its biomimetic therapeutics technology, Cayuga Biotech seeks to harness the body's innate ability to promote healing and improve survival rates, while also reducing disability resulting from trauma.

Cayuga Biotech is a startup focused on the development of innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a major cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting process at the injury site, thereby minimizing the risk of side effects associated with bleeding. Cayuga's pipeline includes a clinic-ready drug designed for life-threatening hemorrhage and additional therapeutics in the discovery stage targeting rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. Through its biomimetic therapeutics technology, Cayuga Biotech seeks to harness the body's innate ability to promote healing and improve survival rates, while also reducing disability resulting from trauma.

Dalton Bioanalytics is a company that specializes in analytical technology aimed at transforming blood analysis and enhancing preventative healthcare. Founded in 2019 and based in Los Angeles, California, Dalton Bioanalytics addresses the inefficiencies and high costs associated with traditional laboratory testing. Its innovative technology digitizes the biochemical composition of blood, allowing for a comprehensive array of health insights derived from a single assay. This capability enables the monitoring of various plasma analytes, including proteins, lipids, electrolytes, and small molecules. By deciphering the biochemical signatures in blood, Dalton Bioanalytics supports the scientific research community in exploring multi-omic biology, thereby facilitating the discovery, development, and delivery of precision medicine.

Ivy Natal is a biotechnology company focused on addressing infertility through innovative reproductive solutions. The company has developed a skin biopsy technology that enables the creation of human egg cells from skin samples. This process activates the existing DNA within skin cells to transform them into healthy egg cells, offering a novel alternative to traditional in vitro methods for producing eggs and sperm. By circumventing the challenges associated with conventional reproductive techniques, Ivy Natal aims to provide couples, including those in same-sex relationships, with the opportunity to have genetically related children.

CASPR Biotech is a San Francisco-based company established in 2018 that specializes in the development of a CRISPR-based platform for diagnosing antimicrobial resistances (AMR) and infectious diseases. The company focuses on creating portable diagnostic kits that utilize proprietary CRISPR Cas enzymes to detect specific DNA and RNA sequences, as well as signature amino acid sequences associated with infectious diseases and genetic mutations. These kits are designed to provide clinicians with a simple, fast, and affordable solution for molecular detection, enhancing the efficiency of disease identification in clinical and hospital settings.

CASPR Biotech is a San Francisco-based company established in 2018 that specializes in the development of a CRISPR-based platform for diagnosing antimicrobial resistances (AMR) and infectious diseases. The company focuses on creating portable diagnostic kits that utilize proprietary CRISPR Cas enzymes to detect specific DNA and RNA sequences, as well as signature amino acid sequences associated with infectious diseases and genetic mutations. These kits are designed to provide clinicians with a simple, fast, and affordable solution for molecular detection, enhancing the efficiency of disease identification in clinical and hospital settings.

Ten63 Therapeutics, Inc. is a biotechnology company based in Chapel Hill, North Carolina, focused on developing potent therapeutics for medically validated yet undruggable targets. Founded in 2017, the company utilizes its innovative platform, COPPER, which combines machine learning-based computational chemistry with advanced physical modeling to explore an extensive chemical space. This approach allows Ten63 Therapeutics to discover novel drug candidates for some of the most lethal diseases by employing proprietary algorithms for scaffold redesign and optimizing chemical design. By integrating these technologies, the company aims to produce durable therapies and improve drug resistance prediction, ultimately addressing challenges in drug development for previously intractable targets.

Intrinsic Medicine, Inc. is a clinical-stage company based in Des Moines, Washington, focused on researching and developing innovative medicines for patients. Formerly known as Lupa Bio, the company specializes in the development of prebiotic drugs aimed at treating various human diseases. Its flagship products, Human Identical Milk Oligosaccharides (HiMOs), are engineered to remain stable in stomach acid and resist degradation in the upper gastrointestinal tract. This unique formulation allows patients to enhance gut health and modulate immune responses effectively. As a venture-backed entity, Intrinsic Medicine operates with a technical and operational platform designed to bring significant medical advancements to patients in an efficient and ethical manner.

Dalton Bioanalytics is a company that specializes in analytical technology aimed at transforming blood analysis and enhancing preventative healthcare. Founded in 2019 and based in Los Angeles, California, Dalton Bioanalytics addresses the inefficiencies and high costs associated with traditional laboratory testing. Its innovative technology digitizes the biochemical composition of blood, allowing for a comprehensive array of health insights derived from a single assay. This capability enables the monitoring of various plasma analytes, including proteins, lipids, electrolytes, and small molecules. By deciphering the biochemical signatures in blood, Dalton Bioanalytics supports the scientific research community in exploring multi-omic biology, thereby facilitating the discovery, development, and delivery of precision medicine.

Ravata Solutions is a medical device company based in Davis, California, specializing in gene delivery systems aimed at enhancing the development of custom animal models. Founded in 2016, Ravata focuses on improving the production of transgenic models that are crucial for pre-clinical research studies. By streamlining the creation of transgenic organisms and optimizing embryo viability, the company aims to accelerate human disease model development, thereby contributing to advancements in drug efficacy and medical genetics research. Through its innovative solutions, Ravata facilitates efficient embryo engineering at a production scale, ultimately supporting researchers in their efforts to understand and address complex health challenges.

BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is dedicated to improving reconstruction options for breast cancer patients post-mastectomy. The company specializes in developing tissue-engineered nipple-areolar complex (NAC) grafts, which are designed to be used during the breast reconstruction phase. These off-the-shelf, acellular NAC grafts serve as a framework for the patient's own cells to regenerate their nipple and areola, providing a more natural outcome. The company is based in New Orleans, Louisiana.

BioROSA Technologies Inc. is a biotechnology company focused on developing diagnostic tools for Autism Spectrum Disorders (ASD). Founded in 2018 and headquartered in Belmont, Massachusetts, the company specializes in creating biologically-based blood tests that assist clinicians in identifying individuals at risk for ASD. By utilizing machine learning to analyze biological data, BioROSA Technologies aims to provide reliable and accurate diagnoses, facilitating early detection and timely treatment. Additionally, the company's technology supports therapeutic trials by evaluating pharmacodynamics and patient stratification, thereby enhancing the overall standard of care for ASD.

Dahlia Biosciences is a biotechnology company founded in 2011 and headquartered in California, United States. It specializes in DNA analysis and diagnostics, focusing on the development of RNA detection tools that facilitate precision medicine research. The company's innovative solutions utilize CRISPR-Cas9 technology to detect multiple DNA and RNA biomarkers directly within cells and tissues. This capability allows researchers to study and isolate cells with high resolution, significantly enhancing the sensitivity and robustness of RNA detection in various applications. Dahlia Biosciences aims to advance research and diagnostic capabilities in the life sciences through its cutting-edge technologies.

Antibiotic Adjuvant, Inc. is a healthcare technology company based in Gainesville, Florida, founded in 2014. The company specializes in developing decision support software aimed at reducing infections and antibiotic resistance in healthcare settings. Its flagship product, SmartSteward, provides a comprehensive platform designed to optimize antibiotic use in real-time. The software caters to healthcare administrators by offering tools and educational resources, supports physicians with relevant prescribing information, and assists nurses through surveillance tools and infection reporting mechanisms. Antibiotic Adjuvant's innovative approach seeks to improve the management of antibiotic prescriptions, addressing the complexities of usage patterns and enhancing resistance control in clinical environments.

CASPR Biotech is a San Francisco-based company established in 2018 that specializes in the development of a CRISPR-based platform for diagnosing antimicrobial resistances (AMR) and infectious diseases. The company focuses on creating portable diagnostic kits that utilize proprietary CRISPR Cas enzymes to detect specific DNA and RNA sequences, as well as signature amino acid sequences associated with infectious diseases and genetic mutations. These kits are designed to provide clinicians with a simple, fast, and affordable solution for molecular detection, enhancing the efficiency of disease identification in clinical and hospital settings.

BiomeSense, Inc. is a Chicago-based company founded in 2018 that focuses on developing a comprehensive platform for microbiome data collection and analysis. Its primary innovation is the GutLab, a "smart bathroom" system designed for continuous, at-home monitoring of the human gut microbiome. This technology is integrated with the MetaBiome time-series analytics platform, offering a seamless end-to-end solution that enables real-time tracking of microbiome changes and their correlation with clinical outcomes. By generating and analyzing extensive longitudinal microbiome datasets, BiomeSense aims to discover and commercialize novel microbiome biomarkers, providing healthcare professionals with a high-resolution microbiome database. This resource supports the development of advanced microbiome-based therapeutics and consumer products, ultimately enhancing precision medicine and improving health outcomes.

NeuroQore, Inc. is a Canadian company based in Ottawa, founded in 2012, that specializes in developing innovative neuromodulation treatment systems aimed at addressing treatment-resistant depression and related neurobehavioral conditions. The company's flagship product is a monophasic repetitive transcranial magnetic stimulation system that utilizes a unique semiconductor switch to emit a novel magnetic pulse. This technology is designed to help patients overcome challenges associated with major depressive disorder and suicidality, ultimately improving their quality of life. NeuroQore collaborates with leading universities and research clinics globally, reflecting its commitment to advancing the field of neuromodulation and transforming the lives of those affected by these debilitating disorders.

Filtricine, Inc., founded in 2017 and based in Santa Clara, California, is a clinical-stage biotechnology company focused on developing innovative therapies for cancer treatment. The company's approach involves targeted nutrient deprivation, which identifies and exploits metabolic vulnerabilities specific to cancer cells. By depleting nutrients critical to cancer growth without using traditional drugs, Filtricine aims to provide effective treatments that minimize harm to healthy cells.

Dahlia Biosciences is a biotechnology company founded in 2011 and headquartered in California, United States. It specializes in DNA analysis and diagnostics, focusing on the development of RNA detection tools that facilitate precision medicine research. The company's innovative solutions utilize CRISPR-Cas9 technology to detect multiple DNA and RNA biomarkers directly within cells and tissues. This capability allows researchers to study and isolate cells with high resolution, significantly enhancing the sensitivity and robustness of RNA detection in various applications. Dahlia Biosciences aims to advance research and diagnostic capabilities in the life sciences through its cutting-edge technologies.

Osiris Bio

BioROSA Technologies Inc. is a biotechnology company focused on developing diagnostic tools for Autism Spectrum Disorders (ASD). Founded in 2018 and headquartered in Belmont, Massachusetts, the company specializes in creating biologically-based blood tests that assist clinicians in identifying individuals at risk for ASD. By utilizing machine learning to analyze biological data, BioROSA Technologies aims to provide reliable and accurate diagnoses, facilitating early detection and timely treatment. Additionally, the company's technology supports therapeutic trials by evaluating pharmacodynamics and patient stratification, thereby enhancing the overall standard of care for ASD.

Filtricine, Inc., founded in 2017 and based in Santa Clara, California, is a clinical-stage biotechnology company focused on developing innovative therapies for cancer treatment. The company's approach involves targeted nutrient deprivation, which identifies and exploits metabolic vulnerabilities specific to cancer cells. By depleting nutrients critical to cancer growth without using traditional drugs, Filtricine aims to provide effective treatments that minimize harm to healthy cells.

Antibiotic Adjuvant, Inc. is a healthcare technology company based in Gainesville, Florida, founded in 2014. The company specializes in developing decision support software aimed at reducing infections and antibiotic resistance in healthcare settings. Its flagship product, SmartSteward, provides a comprehensive platform designed to optimize antibiotic use in real-time. The software caters to healthcare administrators by offering tools and educational resources, supports physicians with relevant prescribing information, and assists nurses through surveillance tools and infection reporting mechanisms. Antibiotic Adjuvant's innovative approach seeks to improve the management of antibiotic prescriptions, addressing the complexities of usage patterns and enhancing resistance control in clinical environments.

Nivien Therapeutics, founded in 2016 and based in Boston, Massachusetts, is a biotechnology company focused on developing innovative therapies to enhance chemotherapy and immunotherapy for patients with resistant cancers. The company is recognized for creating the first small molecule inhibitors of the Hippo signaling pathway, which play a crucial role in its therapeutic strategies. Nivien Therapeutics aims to de-risk the transfer of technology assets from top research institutions and is actively developing a novel platform to improve the efficacy of combined immuno-chemotherapy treatments. Through its advancements, the company seeks to address significant challenges in treating cancer, particularly in cases where conventional therapies have been ineffective.

Dahlia Biosciences is a biotechnology company founded in 2011 and headquartered in California, United States. It specializes in DNA analysis and diagnostics, focusing on the development of RNA detection tools that facilitate precision medicine research. The company's innovative solutions utilize CRISPR-Cas9 technology to detect multiple DNA and RNA biomarkers directly within cells and tissues. This capability allows researchers to study and isolate cells with high resolution, significantly enhancing the sensitivity and robustness of RNA detection in various applications. Dahlia Biosciences aims to advance research and diagnostic capabilities in the life sciences through its cutting-edge technologies.

Scaled Biolabs Inc. is a biotechnology company based in San Francisco, California, specializing in research and development solutions for cell therapies. Established in 2016, the company has developed a Cell Therapy Discovery Engine that leverages microfluidics, automation, and machine learning to facilitate the discovery of advanced cell-based medicines. This innovative platform allows leading biotech and pharmaceutical firms to explore a wide range of experimental parameters simultaneously, yielding valuable insights into cellular processes. By miniaturizing laboratory environments, Scaled Biolabs accelerates the development and manufacturing of novel cell therapies, which enhances clinical outcomes and reduces time to market. Additionally, the company is engaged in creating its own cell therapy assets, including a program focused on iPSC-derived dopaminergic neurons aimed at treating Parkinson’s disease.

Onconetics Pharmaceuticals, Inc. is a biotechnology company focused on developing gene therapies aimed at treating cancer and other genetic disorders. Established in 2016 and located in Mill Valley, California, Onconetics utilizes a unique therapeutic platform that incorporates a genetic switch to activate apoptotic inducers, selectively targeting tumor cells while preserving healthy tissue. The company is dedicated to advancing personalized medicine by integrating established gene therapy techniques with innovative research, striving to create effective treatments that reduce the invasiveness and side effects associated with traditional cancer therapies. Through its efforts, Onconetics aims to enhance patient outcomes and improve the overall quality of life for individuals affected by cancer and genetic conditions.

BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is dedicated to improving reconstruction options for breast cancer patients post-mastectomy. The company specializes in developing tissue-engineered nipple-areolar complex (NAC) grafts, which are designed to be used during the breast reconstruction phase. These off-the-shelf, acellular NAC grafts serve as a framework for the patient's own cells to regenerate their nipple and areola, providing a more natural outcome. The company is based in New Orleans, Louisiana.

Indee Labs is focused on developing innovative hardware for gene delivery, specifically designed to facilitate the efficient development and scalable manufacture of gene-modified cell therapies, such as chimeric antigen receptor T cells. The company has created a non-viral intracellular delivery system that integrates with standard reagents, optimizing the recovery of viable modified cells with minimal disruption. Utilizing microfluidic vortex shedding technology, Indee Labs' system enables the gentle delivery of macromolecules, nucleic acids, and gene-editing complexes to various cell types. The company collaborates with the Australian National Fabrication Facility for its technology development and has established lab space at Bonneville Labs in Berkeley while expanding its operations with a new office in Sydney. Indee Labs has been associated with various prestigious incubators and programs, including NSW Health, IndieBio, Y Combinator, and MBC Biolabs.

Mendel is a clinical AI platform for life sciences and healthcare organizations that deciphers health data with clinician-like logic. It indexes structured and unstructured data and replaces the complexity of querying with the simplicity of chatting.

BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is dedicated to improving reconstruction options for breast cancer patients post-mastectomy. The company specializes in developing tissue-engineered nipple-areolar complex (NAC) grafts, which are designed to be used during the breast reconstruction phase. These off-the-shelf, acellular NAC grafts serve as a framework for the patient's own cells to regenerate their nipple and areola, providing a more natural outcome. The company is based in New Orleans, Louisiana.

Stelvio Therapeutics is a biopharmaceutical company focused on developing innovative therapies for incurable cancers and neurodegenerative diseases. The company utilizes a machine vision and learning platform to drive diseased stem cells to non-diseased states by identifying drugs that induce epigenetic changes. Its proprietary Microscopic Imaging of Epigenetic Landscapes (MIEL) technology facilitates the discovery of small molecules capable of differentiating or reversing cancerous cells into benign types, potentially offering curative outcomes. Founded in 2017 and headquartered in San Diego, California, Stelvio Therapeutics combines scientific creativity, clinical excellence, and professional management to advance novel drug therapies and precision medicine diagnostics, with a particular emphasis on personalized treatments for conditions such as glioblastoma.

Jungla Inc., established in 2016 and headquartered in South San Francisco, is a biotechnology company specializing in molecular function software for healthcare and pharmaceutical industries. It optimizes disease diagnosis by developing advanced functional genomics, computational biophysics, and computer science technologies. Jungla's platform proactively assesses genetic variant risks, providing quantitative insights to complement observational data. This enhances clinical genetic testing accuracy and delivers robust, scalable results. As of July 2019, Jungla operates as a subsidiary of Invitae Corporation.

Scaled Biolabs Inc. is a biotechnology company based in San Francisco, California, specializing in research and development solutions for cell therapies. Established in 2016, the company has developed a Cell Therapy Discovery Engine that leverages microfluidics, automation, and machine learning to facilitate the discovery of advanced cell-based medicines. This innovative platform allows leading biotech and pharmaceutical firms to explore a wide range of experimental parameters simultaneously, yielding valuable insights into cellular processes. By miniaturizing laboratory environments, Scaled Biolabs accelerates the development and manufacturing of novel cell therapies, which enhances clinical outcomes and reduces time to market. Additionally, the company is engaged in creating its own cell therapy assets, including a program focused on iPSC-derived dopaminergic neurons aimed at treating Parkinson’s disease.

Ravata Solutions is a medical device company based in Davis, California, specializing in gene delivery systems aimed at enhancing the development of custom animal models. Founded in 2016, Ravata focuses on improving the production of transgenic models that are crucial for pre-clinical research studies. By streamlining the creation of transgenic organisms and optimizing embryo viability, the company aims to accelerate human disease model development, thereby contributing to advancements in drug efficacy and medical genetics research. Through its innovative solutions, Ravata facilitates efficient embryo engineering at a production scale, ultimately supporting researchers in their efforts to understand and address complex health challenges.

Mendel is a clinical AI platform for life sciences and healthcare organizations that deciphers health data with clinician-like logic. It indexes structured and unstructured data and replaces the complexity of querying with the simplicity of chatting.

NeuroQore, Inc. is a Canadian company based in Ottawa, founded in 2012, that specializes in developing innovative neuromodulation treatment systems aimed at addressing treatment-resistant depression and related neurobehavioral conditions. The company's flagship product is a monophasic repetitive transcranial magnetic stimulation system that utilizes a unique semiconductor switch to emit a novel magnetic pulse. This technology is designed to help patients overcome challenges associated with major depressive disorder and suicidality, ultimately improving their quality of life. NeuroQore collaborates with leading universities and research clinics globally, reflecting its commitment to advancing the field of neuromodulation and transforming the lives of those affected by these debilitating disorders.

Ravata Solutions is a medical device company based in Davis, California, specializing in gene delivery systems aimed at enhancing the development of custom animal models. Founded in 2016, Ravata focuses on improving the production of transgenic models that are crucial for pre-clinical research studies. By streamlining the creation of transgenic organisms and optimizing embryo viability, the company aims to accelerate human disease model development, thereby contributing to advancements in drug efficacy and medical genetics research. Through its innovative solutions, Ravata facilitates efficient embryo engineering at a production scale, ultimately supporting researchers in their efforts to understand and address complex health challenges.

NeuroQore, Inc. is a Canadian company based in Ottawa, founded in 2012, that specializes in developing innovative neuromodulation treatment systems aimed at addressing treatment-resistant depression and related neurobehavioral conditions. The company's flagship product is a monophasic repetitive transcranial magnetic stimulation system that utilizes a unique semiconductor switch to emit a novel magnetic pulse. This technology is designed to help patients overcome challenges associated with major depressive disorder and suicidality, ultimately improving their quality of life. NeuroQore collaborates with leading universities and research clinics globally, reflecting its commitment to advancing the field of neuromodulation and transforming the lives of those affected by these debilitating disorders.

Mendel is a clinical AI platform for life sciences and healthcare organizations that deciphers health data with clinician-like logic. It indexes structured and unstructured data and replaces the complexity of querying with the simplicity of chatting.

Scaled Biolabs Inc. is a biotechnology company based in San Francisco, California, specializing in research and development solutions for cell therapies. Established in 2016, the company has developed a Cell Therapy Discovery Engine that leverages microfluidics, automation, and machine learning to facilitate the discovery of advanced cell-based medicines. This innovative platform allows leading biotech and pharmaceutical firms to explore a wide range of experimental parameters simultaneously, yielding valuable insights into cellular processes. By miniaturizing laboratory environments, Scaled Biolabs accelerates the development and manufacturing of novel cell therapies, which enhances clinical outcomes and reduces time to market. Additionally, the company is engaged in creating its own cell therapy assets, including a program focused on iPSC-derived dopaminergic neurons aimed at treating Parkinson’s disease.

SyntheX, Inc. is a biotechnology company based in San Francisco, California, founded in 2016. It operates a proprietary drug discovery platform that utilizes synthetic biology to expand the druggable proteome, focusing on therapeutic applications in oncology and rare diseases. The platform employs empirical intracellular selection to identify and design compounds that can modulate protein interactions, either disrupting specific protein-protein interactions or facilitating the targeted degradation of proteins through the recruitment of E3 ubiquitin ligases. SyntheX's development portfolio includes stabilized peptide therapeutics, such as STX101 and STX105, aimed at treating cancers that evade chemotherapy through homologous recombination. The company identifies drug targets by analyzing clinical, evolutionary, phenotypic, and structural data, and it maintains both internal oncology projects and collaborative discovery initiatives.

Jungla Inc., established in 2016 and headquartered in South San Francisco, is a biotechnology company specializing in molecular function software for healthcare and pharmaceutical industries. It optimizes disease diagnosis by developing advanced functional genomics, computational biophysics, and computer science technologies. Jungla's platform proactively assesses genetic variant risks, providing quantitative insights to complement observational data. This enhances clinical genetic testing accuracy and delivers robust, scalable results. As of July 2019, Jungla operates as a subsidiary of Invitae Corporation.

Truust Neuroimaging, Inc. specializes in advanced data analysis services for brain research. Established in 2015 and located in San Francisco, California, the company processes and analyzes existing data collected by clients, including multi-electrode array (MEA), electroencephalography (EEG), and electrocorticography (ECOG) data. Truust Neuroimaging enhances the resolution of neuro-imaging systems, significantly improving the ability to diagnose and treat brain-related conditions such as epilepsy and neurodegenerative diseases like Alzheimer's and Parkinson's. The company also provides analysis services for applications in virtual reality, neurostimulation, neuromarketing, and consumer testing. By increasing neuro-imaging resolution, Truust enables researchers and clinicians to make new discoveries and advance technologies such as brain-computer interfaces and augmented cognition.

MYi Diagnostics is a biomedical research company based in San Diego, California, founded in 2015 by Nicholas J. Schork, Devon Cayer, and Kristopher L. Nazor. The company specializes in multiplexed proteomic profiling for precision medicine, focusing on developing single-cell quantification technology to identify unique biomarkers in patient biopsies. This technology aims to replace numerous targeted diagnostics for various conditions, including individual cancers, infectious diseases, metabolic conditions, and other disorders. By generating actionable individualized information, MYi Diagnostics helps streamline clinical intervention strategies, providing healthcare providers with valuable insights for personalized treatment plans.